{"id":"W4407636125","doi":"10.1016/j.ejca.2025.115306","title":"Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Microbial Inactivation Methods","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"EMD Serono; Genentech; PharmaMar; Swedish Orphan Biovitrum; Seagen; Mersana Therapeutics; Clovis Oncology; AstraZeneca; Novocure; Eisai; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Tarveda Therapeutics; Ludwig Institute for Cancer Research; Pfizer; Incyte; MSD Italia; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Intuitive Surgical; Gilead Sciences; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ovarian cancer; Oncology; Medicine; Internal medicine; Randomized controlled trial; Phase (matter); Cancer; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002697707,0.0001554557,0.0004172816,0.0001068612,0.00006311015,0.00002359972,0.0003389553,0.00003248834,0.00004414313],"category_scores_gemma":[0.0007059061,0.0001021995,0.0001503056,0.0003203066,0.00007961302,0.000007788812,0.00007403982,0.000267616,1.749668e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004719318,"about_ca_system_score_gemma":0.0002856145,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002640508,"about_ca_topic_score_gemma":0.0001936043,"domain_scores_codex":[0.9968615,0.001661336,0.000975983,0.000187766,0.000163655,0.0001498159],"domain_scores_gemma":[0.9984434,0.0001070794,0.0008497708,0.0002679681,0.0003007833,0.0000309821],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.06070708,0.0002883125,0.0009066407,0.00001387738,0.0003284388,0.00002364678,0.000887123,0.0006191323,0.8980381,0.00003003674,0.001302238,0.03685537],"study_design_scores_gemma":[0.2468686,0.00108033,0.008581851,0.0003914752,0.00009443193,0.000007606538,0.0005204079,0.00005629848,0.7287651,0.0000357275,0.01338108,0.0002170399],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932099,0.001339694,0.001063606,0.0006335826,0.0004607415,0.0004035411,0.00003137004,0.000002719665,0.002854877],"genre_scores_gemma":[0.9976313,0.0002738686,0.0006147676,0.0003432589,0.0002650282,0.000008884802,0.000002010394,0.00001908461,0.0008418224],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1861616,"threshold_uncertainty_score":0.4167576,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01890757481348089,"score_gpt":0.3472415377581165,"score_spread":0.3283339629446356,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}